Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
60.3M
-
Number of holders
-
164
-
Total 13F shares, excl. options
-
65M
-
Shares change
-
-290K
-
Total reported value, excl. options
-
$1.59B
-
Value change
-
-$4.06M
-
Put/Call ratio
-
0.36
-
Number of buys
-
77
-
Number of sells
-
-82
-
Price
-
$24.44
Significant Holders of Janux Therapeutics, Inc. - Common Stock (JANX) as of Q3 2025
200 filings reported holding JANX - Janux Therapeutics, Inc. - Common Stock as of Q3 2025.
Janux Therapeutics, Inc. - Common Stock (JANX) has 164 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 65M shares
.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (11.2M shares), FMR LLC (9.06M shares), JANUS HENDERSON GROUP PLC (4.7M shares), BlackRock, Inc. (3.73M shares), Paradigm Biocapital Advisors LP (2.92M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.78M shares), VANGUARD GROUP INC (2.42M shares), STATE STREET CORP (1.89M shares), ORBIMED ADVISORS LLC (1.77M shares), and Point72 Asset Management, L.P. (1.71M shares).
This table shows the top 164 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.